IL111721A - Isoxazolines and isoxazoles and pharmaceutical compositions containing them - Google Patents

Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Info

Publication number
IL111721A
IL111721A IL11172194A IL11172194A IL111721A IL 111721 A IL111721 A IL 111721A IL 11172194 A IL11172194 A IL 11172194A IL 11172194 A IL11172194 A IL 11172194A IL 111721 A IL111721 A IL 111721A
Authority
IL
Israel
Prior art keywords
isoxazoles
pharmaceutical compositions
compositions containing
isoxazolines
compounds
Prior art date
Application number
IL11172194A
Other languages
English (en)
Other versions
IL111721A0 (en
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL111721A0 publication Critical patent/IL111721A0/xx
Publication of IL111721A publication Critical patent/IL111721A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11172194A 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them IL111721A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15759893A 1993-11-24 1993-11-24
US23296194A 1994-04-22 1994-04-22
US33792094A 1994-11-10 1994-11-10

Publications (2)

Publication Number Publication Date
IL111721A0 IL111721A0 (en) 1995-01-24
IL111721A true IL111721A (en) 2000-06-01

Family

ID=27388036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11172194A IL111721A (en) 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Country Status (24)

Country Link
EP (2) EP0730590B1 (fr)
JP (1) JPH09505590A (fr)
KR (1) KR100359046B1 (fr)
AT (1) ATE198748T1 (fr)
AU (1) AU695853B2 (fr)
BR (1) BR9408137A (fr)
CA (1) CA2174838A1 (fr)
CZ (1) CZ141996A3 (fr)
DE (1) DE69426604T2 (fr)
DK (1) DK0730590T3 (fr)
ES (1) ES2154326T3 (fr)
FI (1) FI962184A (fr)
GR (1) GR3035610T3 (fr)
HR (1) HRP940952A2 (fr)
HU (1) HUT74690A (fr)
IL (1) IL111721A (fr)
NO (1) NO309768B1 (fr)
NZ (1) NZ276633A (fr)
PL (1) PL182303B1 (fr)
PT (1) PT730590E (fr)
RU (1) RU2149871C1 (fr)
SK (1) SK66696A3 (fr)
TW (1) TW483895B (fr)
WO (1) WO1995014683A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
NZ320963A (en) 1995-09-29 1999-08-30 Lilly Co Eli Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO1997015567A1 (fr) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
CA2240946C (fr) * 1995-12-21 2002-09-10 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline et pyrazoline, inhibiteurs du facteur xa
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
CA2249733A1 (fr) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Inhibiteurs de l'integrine spirocycle
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
AU3640997A (en) 1996-06-19 1998-01-07 Du Pont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
JP2000516230A (ja) * 1996-08-15 2000-12-05 デュポン ファーマシューティカルズ カンパニー Ｉｉｂ／ｉｉｉａ拮抗薬としての環状カルバメート類およびイソオキサゾリジン類
EP0934305A4 (fr) * 1996-08-29 2001-04-11 Merck & Co Inc Antagonistes de l'integrine
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US5738647A (en) 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
US5797867A (en) 1996-09-27 1998-08-25 Becton Dickinson And Company Iontophoretic drug delivery system, including method for activating same for attachment to patient
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EE9900584A (et) * 1997-06-19 2000-08-15 Dupont Pharmaceuticals Company Neutraalse P1 spetsiifilisusrühmaga faktori Xa inhibiitorid
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
US6136833A (en) * 1998-01-16 2000-10-24 Dupont Pharmaceuticals Company Pharmaceutical formulations and process for their preparation
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
CA2333647A1 (fr) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
WO2000029406A2 (fr) 1998-11-18 2000-05-25 Du Pont Pharmaceuticals Company Nouveaux antagonistes du recepteur de fibrinogene a base d'isoxazoline
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
WO2000053264A1 (fr) * 1999-03-11 2000-09-14 Du Pont Pharmaceuticals Company Traitement de la thrombose au moyen d'une combinaison d'un inhibiteur du facteur xa et d'aspirine, d'un activateur tissulaire du plasminogene (tpa), d'un antagoniste de gpiib/iiia, d'heparine a faible masse moleculaire ou d'heparine
AU3625500A (en) 1999-03-11 2000-09-28 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
CA2368630A1 (fr) 1999-04-02 2000-10-12 Ruth R. Wexler Sulfonyles aryles faisant office d'inhibiteurs du facteur xa
AU2002365408B2 (en) 2001-11-26 2008-04-24 Genentech, Inc. Catheter composition and uses thereof
EP1677783A2 (fr) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Antagonistes du recepteur du fibrinogene et leur utilisation
EA011764B1 (ru) 2004-03-05 2009-06-30 Ниссан Кемикал Индастриз, Лтд. Изоксазолинзамещённое производное бензамида и пестицид
AU2005265131B2 (en) * 2004-06-17 2012-02-23 Infinity Discovery, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
AU2005295818A1 (en) 2004-10-12 2006-04-27 Amgen Inc. Novel B1 bradykinin receptor antagonists
EP1817306A1 (fr) 2004-10-13 2007-08-15 Amgen, Inc Triazoles et leur utilisation comme antagonistes du recepteur de la bradykinine b1
AU2006285613B2 (en) 2005-09-02 2011-11-17 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
EP2386547B1 (fr) 2005-12-29 2018-06-20 Lexicon Pharmaceuticals, Inc. Dérivés d'acide aminé multi-cyclique et leurs procédés d'utilisation
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
JP5871449B2 (ja) 2006-11-07 2016-03-01 ジェネンテック， インコーポレイテッド 組織プラスミノゲン活性化因子バリアントの使用
CN102459246B (zh) 2009-04-07 2014-05-07 阿斯利康(瑞典)有限公司 作为治疗剂的异噁唑-3(2h)-酮类似物
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
PL3027600T3 (pl) 2013-07-31 2022-08-08 Novartis Ag 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
TW202003466A (zh) * 2018-04-12 2020-01-16 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3240534B2 (ja) * 1992-06-05 2001-12-17 コニカ株式会社 画像形成方法

Also Published As

Publication number Publication date
AU1098095A (en) 1995-06-13
PL314591A1 (en) 1996-09-16
TW483895B (en) 2002-04-21
EP0970950A3 (fr) 2000-04-05
GR3035610T3 (en) 2001-06-29
NO309768B1 (no) 2001-03-26
DE69426604D1 (de) 2001-02-22
IL111721A0 (en) 1995-01-24
DE69426604T2 (de) 2001-05-10
FI962184A0 (fi) 1996-05-23
ES2154326T3 (es) 2001-04-01
CA2174838A1 (fr) 1995-06-01
HRP940952A2 (en) 1997-04-30
KR100359046B1 (ko) 2003-08-02
RU2149871C1 (ru) 2000-05-27
WO1995014683A1 (fr) 1995-06-01
CZ141996A3 (en) 1996-11-13
PL182303B1 (en) 2001-12-31
EP0730590B1 (fr) 2001-01-17
NO962096D0 (no) 1996-05-23
KR960705794A (ko) 1996-11-08
JPH09505590A (ja) 1997-06-03
FI962184A (fi) 1996-05-23
HU9601414D0 (en) 1996-07-29
ATE198748T1 (de) 2001-02-15
AU695853B2 (en) 1998-08-27
PT730590E (pt) 2001-05-31
HUT74690A (en) 1997-01-28
EP0730590A1 (fr) 1996-09-11
BR9408137A (pt) 1997-08-12
EP0970950A2 (fr) 2000-01-12
DK0730590T3 (da) 2001-03-19
SK66696A3 (en) 1996-11-06
NZ276633A (en) 1998-04-27
NO962096L (no) 1996-05-23

Similar Documents

Publication Publication Date Title
IL111721A0 (en) Isoxazolines and isoxazoles and pharmaceutical compositions containing them
IL118262A0 (en) Isoxazolines and pharmaceutical compositions containing them
DK0730589T3 (da) Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister
IL99537A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
UA29416C2 (uk) Похідні 1,5 - бензодіазепіну, що є антагоністами гастрину та холецистокініну, спосіб їх одержання, фармацевтична композиція
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
MXPA05009103A (es) Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
IL103252A0 (en) Cyclic compounds and pharmaceutical compositions containing them
DK58291D0 (da) Krystalinsk stof og dets fremstilling
WO2005035495A3 (fr) Antagonistes du recepteur du fibrinogene et leur utilisation
WO2000029406A3 (fr) Nouveaux antagonistes du recepteur de fibrinogene a base d'isoxazoline
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
GB9412548D0 (en) Chemical compounds
ATE130289T1 (de) 1,3-diphenyl-2-propin-1-one.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed